ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,030Medicare Part D Prescriptions Filled, Including Refills

Rank: 108 out of 663

$332K Total Retail Price of All Prescriptions

Rank: 192 out of 663

202 Patients Receiving at Least One Drug in Part D
95%Patients 65 Years and Older
72% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Colorado
Lower avg

Schedule Two
Controlled Substances

22% of this provider’s 202 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

12% of this provider’s 202 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

1% of this provider’s 7,540 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$41 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

40 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Colorado
WARFARIN SODIUM 520 511 1 8
LEVOTHYROXINE SODIUM 443 404 2 3
FUROSEMIDE 369 357 3 7
METOPROLOL TARTRATE 238 238 4 11
LISINOPRIL 213 201 5 2
VANCOMYCIN HCL 176 176 6 174
HYDROCODONE-ACETAMINOPHEN 168 168 S3 7 6
AMLODIPINE BESYLATE 167 164 8 5
SIMVASTATIN 147 134 9 1
CITALOPRAM HBR 122 113 10 18
DONEPEZIL HCL 120 115 11 40
QUETIAPINE FUMARATE 109 109 12 69
TRAMADOL HCL 108 108 13 17
ALBUTEROL SULFATE 105 103 14 177
GABAPENTIN 104 101 15 20
PAROXETINE HCL 99 99 16 68
OMEPRAZOLE 98 94 17 4
METFORMIN HCL 93 92 18 9
POTASSIUM CHLORIDE 91 88 19 23
MIRTAZAPINE 90 74 20 52
CEPHALEXIN 86 79 21 119
ESCITALOPRAM OXALATE 81 71 22 77
KLOR-CON M20 80 80 23 70
LEVOFLOXACIN 80 71 23 92
IPRATROPIUM-ALBUTEROL 77 67 25 108
LANTUS 74 74 26 48
HYDROMORPHONE HCL 71 71 S2 27 151
SPIRONOLACTONE 70 65 28 58
KLOR-CON M10 69 69 29 139
FAMOTIDINE 67 67 30 76
POLYETHYLENE GLYCOL 3350 63 62 31 82
DIGOXIN 62 62 32 50
NAMENDA 62 57 32 57
SERTRALINE HCL 61 59 34 35
OXYCODONE HCL 61 44 S2 34 41
SPIRIVA 61 59 34 62
LYRICA 60 60 37 96
LIDODERM 60 60 37 67
PANTOPRAZOLE SODIUM 57 57 39 45
ALENDRONATE SODIUM 57 57 39 15
NYSTATIN 56 51 41 124
NOVOLOG 56 47 41 143
KLOR-CON 10 54 54 43 160
TAMSULOSIN HCL 53 53 44 24
MORPHINE SULFATE ER 50 50 S2 45 51
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.